A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.
Summary
The study was to determine the safe and effective dose of TBC3711 in patients with uncontrolled high blood pressure while already taking blood pressure medications.
Timeline
- Start
- 2006-01
- Primary completion
- 2008-08
- Completion
- 2008-08
Outcome
Mixed primary results
Stopped: “See termination reason in detailed description.”
registry analysis (superiority or other test); Placebo vs TBC3711 10 mg; p = 0.044; LS Mean Difference 5.62 (95% CI 0.17 to 11.08); ANCOVA NCT00272961 ↗
registry analysis (superiority or other test); Placebo vs TBC3711 50 mg; p = 0.970; LS Mean Difference 0.21 (95% CI -11.16 to 11.59); ANCOVA NCT00272961 ↗
registry analysis (superiority or other test); Placebo vs TBC3711 100 mg; p = 0.0269; LS Mean Difference 224.89 (95% CI 27.5 to 422.3); ANCOVA NCT00272961 ↗
registry analysis (superiority or other test); Placebo vs TBC3711 50 mg; p = 0.2274; LS Mean Difference 114.77 (95% CI -75.2 to 304.8); ANCOVA NCT00272961 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TBC3711 | Unknown | 10 mg | — |
| Subject | TBC3711 | Unknown | 50 mg | — |
| Subject | TBC3711 | Unknown | 100 mg | — |
| Subject | TBC3711 | Unknown | 200 mg | — |